By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Head Office
Technologielaan 3
Leuven    B - 3001  Belgium
Phone: 32-16-39-60-60 Fax: 32-16-39-60-70



Company News
TiGenix: Convening Notice To The Extraordinary Shareholders' Meeting To Be Held On 2 June 2015 5/13/2015 9:48:13 AM
USPTO Issues Key US Patent To TiGenix For The Use Of Adipose-Derived Stromal Cells In The Treatment Of Fistulas 4/8/2015 9:39:10 AM
TiGenix: Convening Notice To The Annual And The Extraordinary Shareholders' Meeting To Be Held On 20 April 2015 3/20/2015 7:26:11 AM
TiGenix Reports Its Full Year 2014 Results 3/17/2015 7:41:03 AM
TiGenix Completes Treatment In Phase I Sepsis Challenge Trial With Cx611 3/12/2015 7:20:06 AM
TiGenix's Phase III Trial Design For Cx601 Endorsed By President-Elect Of ECCO 2/23/2015 7:18:15 AM
TiGenix And Lonza Group Ltd. (LZAGY.PK) Sign Agreement For The Manufacture Of Stem Cell-Based Treatment Of Complex Perianal Fistulas In Crohn's Disease 2/12/2015 7:32:55 AM
TiGenix Participates In Key Conferences In The First Half Of 2015 2/2/2015 9:03:11 AM
European Patent Office Issues Key Patent To TiGenix For Expanded Adipose-Derived Stem Cell Compositions 1/22/2015 7:40:09 AM
TiGenix Submits Its Pivotal US Trial Design For Cx601 To The FDA For Special Protocol Assessment 12/22/2014 7:15:29 AM